Renal Cell Carcinoma
Conditions
Brief summary
The hypothesis of this study are as follows: * Prognostic evaluation of patients based on an integrative model provides better assessment of overall survival, and thus improves setting of care goals. * In a routine care population, antitumour drugs may have a significant impact on overall survival through their targeted antitumor effect, but also through their toxicity profile and their impact on comorbidities. * The optimization of patient support (supportive care, drug tolerance monitoring) can have an impact on the prognosis.
Interventions
None listed
Sponsors
Centre Hospitalier Universitaire de Besancon
Study design
Observational model
COHORT
Time perspective
RETROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. Patients with locally advanced or metastatic renal cell carcinoma 2. Whose first-line treatment included at least one anti-angiogenic agent (tyrosine kinase inhibitor or monoclonal antibodies) and / or an mTOR inhibitor; 3. Whatever was the overall ECOG-PS score (Eastern Cooperative Oncology Group Performance Status) at treatment initiation time 4. With first-line treatment carried out between 2007 and June 2016.
Exclusion criteria
1. Patient previously treated with only one cytokine (Interferon α2a, high-dose interleukin-2) 2. Refusal of processing of personal data
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Overall survival after the first line of treatment | year 11 | Time elapsed between initiation date for 2nd line treatment et the date of death, whatever the cause. |
Countries
France
Outcome results
None listed